EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

Giorgio Frega, Fernando P Cossio iD, Jesus M Banales, Vincenzo Cardinale, Rocio I R Macias iD, Chiara Braconi iD, Angela Lamarca

Cells · 2023

DOI: 10.3390/cells12162098 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cells, 2023. Verfasst von Giorgio Frega und 6 weiteren Autor:innen. Beteiligte Einrichtung: Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Society of Medical Oncology (SEOM) Fellowship Program (Return Fellowship), European Union’s Horizon 2020 Research and Innovation Program, Instituto de Salud Carlos III, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has recently been incorporated into the spectrum of biliary tract cancer (BTC) treatment. The identification of predictive response biomarkers is essential in order to identify those patients who may benefit most from this novel treatment option. Here, we propose a systematic literature review and a meta-analysis of PD-1, PD-L1, and other immune-related biomarker expression levels in patients with BTC.

Methods

Prisma guidelines were followed for this systematic review and meta-analysis. Eligible studies were searched on PubMed. Studies published between 2017 and 2022, reporting data on PD-1/PD-L1 expression and other immune-related biomarkers in patients with BTC, were considered eligible.

Results

A total of 61 eligible studies were identified. Despite the great heterogeneity between 39 studies reporting data on PD-L1 expression, we found a mean PD-L1 expression percentage (by choosing the lowest cut-off per study) of 25.6% (95% CI 21.0 to 30.3) in BTCs. The mean expression percentages of PD-L1 were 27.3%, 21.3%, and 27.4% in intrahepatic cholangiocarcinomas (iCCAs—15 studies), perihilar–distal CCAs (p/dCCAs—7 studies), and gallbladder cancer (GBC—5 studies), respectively. Furthermore, 4.6% (95% CI 2.38 to 6.97) and 2.5% (95% CI 1.75 to 3.34) of BTCs could be classified as TMB-H and MSI/MMRd tumors, respectively.

Conclusion

From our analysis, PD-L1 expression was found to occur approximately in 26% of BTC patients, with minimal differences based on anatomical location. TMB-H and MSI molecular phenotypes occurred less frequently. We still lack a reliable biomarker, especially in patients with mismatch-proficient tumors, and we must need to make an effort to conceive new prospective biomarker discovery studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsBile Duct NeoplasmsHumansB7-H1 AntigenProgrammed Cell Death 1 ReceptorImmunotherapyBiomarkersBile Ducts, Intrahepatic

Stichwörter der Autor:innen

biliary cancerimmunotherapypredictive biomarkers

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorBiomarkers

Autor:innen und Institutionen

  • Osteoncology, Soft Tissue and Bone Sarcomas, Innovative Therapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
  • Department of Organic Chemistry I, Center of Innovation in Advanced Chemistry (ORFEO-CINQA), University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), 48940…
  • Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), Ikerbasque, 48940 San Sebastian, Spain.
  • National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31009 Pamplona, Spain.
  • Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Rome, Italy.

ORCID-Profile: Fernando P Cossio, Rocio I R Macias, Chiara Braconi

Förderung

  • Spanish Society of Medical Oncology (SEOM) Fellowship Program (Return Fellowship)
  • European Union’s Horizon 2020 Research and Innovation Program
  • Instituto de Salud Carlos III, Spain
  • European Regional Development Fund

Zitieren

APA

Frega, G., Cossio, F. P., Banales, J. M., Cardinale, V., Macias, R. I. R., Braconi, C., & Lamarca, A. (2023). Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. Cells. https://doi.org/10.3390/cells12162098

Vancouver

Frega G, Cossio FP, Banales JM, Cardinale V, Macias RIR, Braconi C, et al. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. Cells. 2023. doi:10.3390/cells12162098

BibTeX
@article{Frega2023,
  author = {Frega, Giorgio and Cossio, Fernando P and Banales, Jesus M and Cardinale, Vincenzo and Macias, Rocio I R and Braconi, Chiara and Lamarca, Angela},
  title = {Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12162098}
}
Kostenlos starten →